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OBJECTIVE—We performed a retrospective analysis of a national cohort of veterans with
diabetestobetterunderstandregional,geographic,andracial/ethnicvariationindiabetescontrol
as measured by HbA1c.
RESEARCH DESIGN AND METHODS—A retrospective cohort study was conducted
in a national cohort of 690,968 veterans with diabetes receiving prescriptions for insulin or oral
hypoglycemic agents in 2002 that were followed over a 5-year period. The main outcome mea-
sures were HbA1c levels (as continuous and dichotomized at $8.0%).
RESULTS—Relative to non-Hispanic whites (NHWs), HbA1c levels remained 0.25% higher
in non-Hispanic blacks (NHBs), 0.31% higher in Hispanics, and 0.14% higher in individuals
with other/unknown/missing racial/ethnic group after controlling for demographics, type of
medication used, medication adherence, and comorbidities. Small but statistically signiﬁcant
geographic differences were also noted with HbA1c being lowest in the South and highest in
the Mid-Atlantic. Rural/urban location of residence was not associated with HbA1c levels. For
the dichotomous outcome poor control, results were similar with race/ethnic group being
strongly associated with poor control (i.e., odds ratios of 1.33 [95% CI 1.31–1.35] and 1.57
[1.54–1.61] for NHBs and Hispanics vs. NHWs, respectively), geographic region being
weakly associated with poor control, and rural/urban residence being negligibly associated
with poor control.
CONCLUSIONS—In a national longitudinal cohort of veterans with diabetes, we found
racial/ethnic disparities in HbA1c levels and HbA1c control; however, these disparities were
largely, but not completely, explained by adjustment for demographic characteristics, medica-
tion adherence, type of medication used to treat diabetes, and comorbidities.
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D
iabetesaffects more than 23 million
Americans, is the seventh leading
cause of death in the U.S., and is
prevalent worldwide (1,2). However, de-
spite decades of effective treatments for di-
abetes, control rates for the disease remain
below goals set by experts (3,4). A number
of studies report higher HbA1c levels in
African Americans and Hispanics relative
to non-Hispanic whites (NHWs) (5–9).
Current proposed mechanisms for
racial/ethnic disparities in HbA1c levels
relate to both glucose control and glucose-
independent variability in HbA1c levels
(5,6,9). Nevertheless, the social determi-
nants of poor adherence need to be eluci-
dated to more adequately understand
why Hispanics and non-Hispanic blacks
(NHBs) have problems with poor control
of their diabetes even when access to care
is not a factor. Racial disparities in access
to and use of medical care, and provider
behavior are lower in the Veterans Health
Administration (VHA) than outside the
VHA (10). Studies have indicated that
quality of care for diabetes is higher in
the VHA than outside the VHA (11).
In a recent publication by our group
based on a cohort of 8,813 NHW and
NHBveteransobtainingcareataVeterans
Administration (VA) facility in the south-
eastern U.S., we reported a mean differ-
ence in HbA1c levels of 0.43% between
NHWandNHBveteransafteradjustment
for demographic factors and comorbidi-
ties, but not type of medication used to
treat diabetes or medication adherence
(12).
Few studies have examined regional
or geographic variations in HbA1c (13–
15). Even within the VA, rural residents
have disparities in access to care com-
pared with urban residents because of
distance to VA facilities (16). Moreover,
there are geographic differences in the
incidence of diabetes, with levels being
higher in the Stroke Belt, composed of
the southeastern states, compared with
the rest of the U.S. (17). To address this
gapintheliterature,weperformedaret-
rospective analysis of a national cohort
of more than 600,000 diabetic veterans
during a 5-year period of observation.
We hypothesized that HbA1c levels
would be higher in the south, that
HbA1c levels would be higher in rural
than in urban areas, and that HbA1c lev-
els would be higher in NHBs and His-
panics than in NHWs. In addition, we
hypothesized that HbA1c levels would
be related to type of medication used
to treat diabetes and would vary over
time.
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ORIGINAL ARTICLERESEARCH DESIGN AND
METHODS
Study population
An a t i o n a lc o h o r to fv e t e r a n sw i t ht y p e2
diabetes was created by linking patient
and administrative ﬁles from the VHA
National Patient Care and Pharmacy Ben-
eﬁts Management databases. The Phar-
macy Beneﬁts Management database
includes use information for every pre-
scription ﬁlled in the VA. Veterans were
included in the cohort if they had type 2
diabetes deﬁned by two or more Interna-
tional Classiﬁcation of Diseases, Ninth Re-
vision (ICD-9) codes for diabetes (250,
357.2,362.0,and366.41)intheprevious
24 months (2000 and 2001) and during
2002 from inpatient stays or outpatient
visits on separate days (excluding codes
from laboratory tests and other nonclini-
cian visits), and prescriptions for insulin
or oral hypoglycemic agents (VA classes
HS501 or HS502, respectively) in 2002
(18). Veterans identiﬁed as having type
2 diabetes by ICD-9 codes were excluded
from the cohort if they did not have pre-
scriptionsfordiabeticmedications(HS501
or HS502) in 2002 (see Supplementary
Fig. 1 for cohort deﬁnition). The datasets
werelinkedusingpatientscrambledSocial
Security Numbers. When the data were
merged and limited to include complete
adherence data, this resulted in a cohort
of 690,968 veterans, of whom 72.86%
were NHW, 12.85% were NHB, and
5.11%wereHispanicwithtype2diabetes.
There were also 9.18% of veterans with
missing or unknown race/ethnicity infor-
mation. For a comparison of the 690,698
in our study population with those veter-
ans with type 2 diabetes who were not us-
ing diabetes medication (n = 201,255), see
SupplementaryTable1.Thestudywasap-
proved by our institutional review board
and local VA Research and Development
committee.
Outcome measure
The primary outcome was HbA1c level.In
addition, poor control was deﬁned as
HbA1c $8.0%.
Primary covariates
The primary covariates of interest were
1) race/ethnicity, classiﬁed as NHW,
NHB, Hispanic, and other/unknown/
missing; 2) location of residence (urban
and rural/highly rural) (19); and 3)r e -
gion, which accounts for the ﬁve geo-
graphic regions of the country based on
theVHAVeteran’sIntegratedServiceNet-
works (VISNs): Northeast (VISNs 1, 2,
and 3), Mid-Atlantic (VISNs 4, 5, 6, 9,
and 10), South (VISNs 7, 8, 16, and 17),
Midwest (VISNs 11, 12, 15, 19, and 23),
andWest(VISNs18,20,21,and22)(20).
The race covariate was retrieved from the
2002 outpatient and inpatient Medical
SASdatasets.Whenmissingorunknown,
the variable was supplemented using the
inpatient 2003 Medical SAS dataset ﬁelds
for race, the outpatient 2004 Medical SAS
dataset ﬁelds for race, and the VA Vital
StatusCenters forMedicareandMedicaid
Services ﬁeld for race.
Demographic variables
Age, sex, marital status (i.e., single or mar-
ried),andpercentageservice-connectedness
(i.e., degree of disability due to illness or
injury that was aggravated by or incurred
in military service) were available.
Medication type and medication
possession ratio
Veterans were classiﬁed as to whether
they were taking insulin only, insulin and
oral hypoglycemic agents, or oral hypo-
glycemic agents only. Annual medication
possession ratio (MPR) was calculated
and deﬁned as the number of days supply
divided by 365 days (or if deceased
during that year, the number ofdaysuntil
death) over the study period for each
veteran for insulin or oral hypoglycemic
agents (VA classes HS501 or HS502, re-
spectively). If MPR exceeded one, MPR
was set to one. In addition, MPR was
dichotomized at .80%.
Comorbidity
Variables included substance abuse, ane-
mia, cancer, cerebrovascular disease, con-
gestiveheartfailure,cardiovasculardisease,
depression, hypertension, hypothyroid-
ism, liver disease, lung disease, ﬂuid and
electrolyte disorders, obesity, psychoses,
peripheral vascular disease, and other
(AIDS, rheumatoid arthritis, renal failure,
peptic ulcer disease and bleeding, weight
loss),andweredeﬁnedaccordingtoICD-9
codes at entry into the cohort.
Statistical analysis
Models for the relationship between
HbA1c and race, urban/rural residence,
and VISN were developed in a sequential
fashion. We used a generalized linear
model approach (lmer function in R) to
ﬁt the models for HbA1c as a response
variable with race/ethnicity, location of
residence (urban/rural), and region as
main independent variables of interest
with adjustment for potential confound-
ers. The general model had the following
regression format, E(Yi|Xi,Zi)=g
21(Xib+
Zigi),wheregisamonotonelinkfunction
and Yi is the response for the i
th subject
with Ti (Ti =1 , ...,5) repeated measure-
ments,XiandZirepresentvectorsofﬁxed
and random effect covariates, respec-
tively, and g is considered as the identity
link resulting in a linear mixed model for
the continuous HbA1c outcome and the
logitlinkforthedichotomousHbA1c out-
come. A person-level random effect was
included in all models to account for
within-individual correlations. This ap-
proach accommodates a wide range of
distributional assumptions, multilevel
data such as longitudinal measurements
onsubjects,measurementofsubjectsatdif-
ferent time points, modeling individual
leveleffects,missingdata,andtimevarying
or invariant covariates (21). Model ﬁtw a s
assessed using plots of residuals and pre-
dictedvalues.Allstatisticaltestsusedatwo-
tailed a = 0.05 level of signiﬁcance and
were performed in R, version 2.11.0.
RESULTS—The study population con-
sisted of 690,968 veterans with diabetes
receiving prescriptions for insulin or oral
hypoglycemic agents (VA classes HS501
orHS502,respectively)in2002that were
followed until death, loss to follow-up, or
through December 2006. During the
follow-up period, 24.65% of individuals
in the cohort died. Table 1 shows the
characteristics of the sample.
Relative to NHWs, HbA1c was 0.45%
higher in NHBs, 0.38% higher in Hispan-
ics, and 0.57% higher in individuals with
other/unknown/missing racial/ethnic
group after adjusting for trends over
time (Table 2). After further adjusting
for demographic factors, including loca-
tion of residence and geographic region,
racial/ethnic HbA1c differences were
moderately attenuated and changes over
time were altered, but the pattern re-
mained similar. Adding medication type,
MPR, and comorbidities to the ﬁnal
model altered racial/ethnic group HbA1c
differences only slightly. A small, but sta-
tistically signiﬁcant difference in HbA1c
with respect to rural/urban residence
was found with rural residence being as-
sociated with slightly higher HbA1c than
urban residence. Small, but statistically
signiﬁcant regional differences were also
noted with HbA1c being lowest in the
South and highest in the Mid-Atlantic.
Adding medication type (i.e., insulin
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Egede and Associatescombined with oral hypoglycemic medi-
cation, insulin only, and hypoglycemic
medication only), MPR, and comorbidi-
tiestotheﬁnal model altered regionaldif-
ferences in HbA1c levels moderately, but
HbA1c levels remained lowest in the South
and highest in the Mid-Atlantic. Rural/
urbandifferenceswereattenuated.Medica-
tion type was associated with HbA1c levels.
Relative to individuals using only oral
hypoglycemic medications, HbA1c was
0.53% higher in individuals using insulin
onlyand0.81%higherinindividualsusing
insulin combined with oral hypoglycemic
medication. MPR was not signiﬁcantly as-
sociated with HbA1c levels.
RelativetoNHWs,theodds of having
uncontrolled versus controlled HbA1c
(deﬁned as HbA1c .8.0%) was 1.71-fold
(95%CI1.68–1.73)higherinNHBs,1.63-
fold (1.60–1.66) higher in Hispanics, and
1.91-fold (1.87–1.94) higher in individ-
uals with other/unknown/missing racial/
ethnic group after adjusting for trends
over time (Table 3). The odds of having
uncontrolled versus controlled HbA1c ini-
tially decreased, but then increased over
time. After further adjusting for demo-
graphic factors (including location of res-
idence and geographic region), changes
over time were altered, but the pattern re-
mained similar. Odds ratios relative to
NHWs for uncontrolled HbA1c were
1.35 (1.33–1.37), 1.53 (1.50–1.57), and
1.14 (1.11–1.16) for NHBs, Hispanics,
and individuals with other/unknown/
missing racial/ethnic group over time, re-
spectively(Fig.1). Theoddsof having un-
controlled HbA1c levels decreased with
increasing age, were lower in women
thanmen,andwerehigherinsingleversus
married individuals, but were not associ-
ated with service-connected disability.
Small, but statistically signiﬁcant differ-
ences in the odds of having uncontrolled
HbA1c with respect to rural/urban resi-
dence were found; rural residence was as-
sociated with a slightly higher odds of
having uncontrolled HbA1c compared
with urban residence (Fig. 1). Small, but
statistically signiﬁcant regional differences
were also noted with the odds of having
uncontrolledHbA1clowestintheMidwest
and highest in the Mid-Atlantic (Fig. 1).
Adding medication type, MPR, and co-
morbidities to a ﬁnal model altered
changes in HbA1c control over time, racial/
ethnic group differences in HbA1c control,
and regional differences in HbA1c con-
trol only slightly. Medication type was
associated with HbA1c control relative to
individuals using only oral hypoglycemic
medications. The odds of having uncon-
trolled HbA1c were 2.35-fold (2.32–2.38)
higher in individuals using insulin only
and 3.53-fold (3.49–3.57) higher in indi-
viduals using insulin combined with oral
hypoglycemic medication. In addition,
having an MPR less than 80% was associ-
ated with a 5% increase in the odds of
having uncontrolled HbA1c (odds ratio
1.05 [1.04–1.06]).
In the ﬁnal models, HbA1c levels and
control (i.e., deﬁned as HbA1c #8.0%)
were also associated with comorbidities;
however,thestrengthanddirectionofthe
association depended on the comorbidity
(Tables 2 and 3).
CONCLUSIONS—The ﬁndings of
this study are important for the following
reasons. First, few prior studies have
examined geographic or regional differ-
ences in either HbA1c testing or HbA1c
levels, and prior national studies have
not examined geographic or regional dif-
ferences in HbA1c levels. Moreover, prior
national studies on racial/ethnic differ-
ences in HbA1c levels at the VA have not
f o c u s e do nH b A 1c levels in Hispanics
relative to NHWs or adjusted for type of
diabetes medication, medication adher-
ence, or comorbidities. These unique fea-
tures of our study combined with the
unique setting of the VA, where racial/
ethnic disparities in access to and use of
medical care, and provider behavior are
limited,arenovelaspectsofourstudythat
contribute to the literature and to our
understanding of factors that inﬂuence
HbA1c levels. Finally, understanding geo-
graphic and regional differences in HbA1c
levels and control may have important
policy implications if we are able to iden-
tify factors within each setting that con-
tribute to differences.
Despite equal access in the VHA, we
report longitudinal racial/ethnic differ-
ences in HbA1c. A major contribution of
this study is the ability to control for de-
mographicfactors,typeofmedicationused
(as a surrogate for disease severity), med-
ication adherence, and a variety of comor-
bidities. In addition, the study included a
large sample of Hispanics. Previous VA
studies have not examined HbA1c levels
in Hispanics relative to NHWs or NHBs.
Notably, our adjusted reported mean dif-
ference in HbA1c levels between NHBs
and NHWs is smaller (0.25%) than that
reported in a recent cross-sectional study
(0.47%), which adjusted for plasma glu-
cose levels, demographics, and a few
other variables, not including type of
Table 1—Sample characteristics
Mean/percent
(SD/SE)
Mean HbA1c 7.48 (1.63)
Mean minimum HbA1c 6.96 (1.49)
Mean maximum HbA1c 8.04 (2.13)
Racial/ethnic group
NHW 72.86 (0.07)
NHB 12.85 (0.11)
Hispanic 5.11 (0.12)
Other 9.18 (0.12)
Rural residence 38.87 (0.09)
Geographic region
Northeast 11.17 (0.11)
Mid-Atlantic 22.57 (0.11)
South 30.00 (0.11)
Midwest 21.12 (0.11)
West 14.88 (0.11)
Age 65.77 (11.28)
Male 97.81 (0.02)
Percentage
service-connected
disability 12.26 (27.21)
Married 65.58 (0.07)
Medication type used to
control diabetes
Oral hypoglycemics 69.37 (0.07)
Insulin 14.28 (0.11)
Insulin and oral
hypoglycemics 16.35 (0.11)
MPR all (%) 70.94 (20.53)
MPR 501 only (%) 64.65 (28.26)
MPR 502 only (%) 73.04 (32.34)
MPR 501 and 502 (%) 66.04 (20.36)
Comorbidities
Substance abuse 3.79 (0.12)
Anemia 7.48 (0.12)
Cancer 7.60 (0.12)
Cerebrovascular
disease 11.68 (0.11)
Congestive heart
failure 11.59 (0.11)
Cardiovascular
disease 3.62 (0.12)
Depression 12.42 (0.11)
Hypertension 77.61 (0.06)
Hypothyroidism 6.17 (0.12)
Liver disease 3.14 (0.12)
Lung conditions 13.88 (0.11)
Electrolyte disorders 4.95 (0.12)
Obesity 12.48 (0.11)
Psychoses 4.31 (0.12)
Peripheral vascular
disease 12.02 (0.11)
Other disease 3.72 (0.12)
Dead 24.65 (0.11)
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Regional, geographic, and ethnic variationmedication used (9). The magnitude of
the racial/ethnic disparity was similar in
our study as in a smaller VA study (n =
4,080) that reported glucose-independent
mean differences in HbA1c levels between
NHBs and NHWs of ;0.2% among indi-
vidualsreceivingconsistentprimarycareat
the VA (22).
Studies outside the VHA have consis-
tently reported racial/ethnic disparities
(7). A meta-analysis of disparities in
HbA1c levels between NHWs and NHBs
with diabetes, which included 11 articles
published between 1993 and 2005, re-
ported crude unadjusted HbA1c differ-
ences between NHWs and NHBs of
;0.65% (7). Our adjusted estimate of
mean difference in HbA1c between
NHBsandNHWs(0.25%)issubstantially
lower (7). Studies conducted outside a
managed care setting generally report
wider disparities. One smaller (n =
1,034) study conducted in a nationally
representativesamplereportedmeandif-
ferences in HbA1c levels of 0.73% be-
tween NHBs and NHWs and 0.74%
betweenLatinosandNHWsafteradjusting
fordemographics,clinicalcharacteristics,
access and quality of care, health behav-
iors, medication adherence, and self-
management attitudes (23).
HbA1c levels were highly correlated
with average glucose levels over the pro-
ceeding3-monthperiod(24);however,glu-
cose is not the only factor that affects HbA1c
levels. Current proposed mechanisms for
racial/ethnic disparities in HbA1c levels
are physiologic, genetic, socioeconomic,
and cultural in nature.The social determi-
nants of poor adherence need to be better
elucidated to adequately understand why
Hispanics and NHBs have more problems
with poor control of their diabetes even
when access to care is not a factor. How-
ever, in considering mechanisms in racial/
ethnic disparities in HbA1c levels, it is
important to remember that glucose-
adjusted racial and ethnic disparities in
HbA1c are estimated to be less than 0.5%
in individuals with diabetes (5,6,9).
Few studies have examined geo-
graphic or regional differences in HbA1c
testing or control (13–15). Results from
thesestudiesindicatethatHbA1ctestingis
Table 2—Regression coefﬁcient estimates and 95% CIs for HbA1c in veterans with type 2 diabetes
Model 1* Model 2* Final model*
Intercept 7.424 (7.411–7.437) 7.534 (7.518–7.551) 7.4205 (7.4027–7.4383)
Time 20.136 (20.144 to 20.127) 20.160 (20.168 to 20.151) 20.1603 (20.1689 to 20.1517)
Time-squared 0.027 (0.026–0.029) 0.029 (0.028–0.030) 0.0279 (0.0265–0.0292)
Racial/ethnic group
NHB 0.454 (0.444–0.465) 0.265 (0.254–0.276) 0.2529 (0.2424–0.2634)
Hispanic 0.375 (0.360–0.391) 0.317 (0.301–0.333) 0.3139 (0.2987–0.3290)
Other 0.570 (0.557–0.582) 0.142 (0.129–0.155) 0.1799 (0.1674–0.1924)
Residence (rural vs. urban) 0.010 (0.002–0.017) 0.0046 (20.0025 to 0.0117)
Geographic region (reference: Northeast)
South 20.054 (20.066 to 20.041) 20.0797 (20.0915 to 20.0678)
Mid-Atlantic 0.040 (0.027–0.053) 0.0131 (0.0007–0.0255)
Midwest 20.026 (20.039 to 20.013) 20.0703 (20.0829 to 20.0578)
West 20.027 (20.041 to 20.014) 20.0605 (20.0737 to 20.0472)
Age (1-year increase)† 20.031 (20.031 to 20.031) 20.0261 (20.0265 to 20.0258)
Sex (female vs. male) 20.029 (20.052 to 20.005) 20.0118 (20.0346 to 0.0110)
SCD (1% increase) 20.001 (20.002 to 20.001) 20.0014 (20.0015 to 20.0113)
Marital status (single vs. married) 0.096 (0.088–0.103) 0.1007 (0.0934–0.1079)
Medication type used to control diabetes (reference: oral hypoglycemics)
Insulin 0.5326 (0.5239–0.05414)
Insulin and oral hypoglycemics 0.8146 (0.8070–0.8221)
Nonadherence (MPR #80% vs. .80%) 0.0031 (20.0021 to 0.0084)
Comorbidities (disease vs. no disease)
Substance abuse 0.0215 (0.0033–0.0397)
Anemia 20.1592 (20.1725 to 20.1460)
Cancer 20.0577 (20.0708 to 20.0447)
Cerebrovascular disease 20.0685 (20.0792 to 20.0577)
Congestive heart failure 0.0794 (0.0682 to 0.0907)
Cardiovascular disease 0.0334 (0.0151–0.0516)
Depression 0.0464 (0.0360–0.0568)
Hypertension 20.0810 (20.0893 to 20.0727)
Hypothyroidism 20.0331 (20.0470 to 20.0192)
Liver disease 20.2818 (20.3013 to 20.2624)
Lung conditions 20.0171 (20.0270 to 20.0072)
Electrolyte disorders 0.0230 (0.0070–0.0390)
Obesity 20.0465 (20.0565 to 20.0365)
Psychoses 20.0572 (20.0742 to 20.0402)
Peripheral vascular disease 0.0255 (0.0149–0.0361)
Other disease 20.1578 (20.1759 to 20.1397)
SCD, service-connected disability. *Includes a random subject term. †Age centered.
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Egede and Associateslower in rural than urban areas, especially
in the rural south (13–15). In one study
conducted in Oregon, HbA1ctesting rates
in areas with rural health clinics were
higher than in areas without rural health
clinics and similar to levels in urban areas
(15).Thus,theremaybeimportantpolicy
implications given the geographic differ-
ences that we found.
Strengths of our study include the
study population, all veterans with type 2
diabetes receiving care at the VHA had
prescriptions for diabetes medication in
2002,thelongitudinaldesignwith5years
of follow-up data, the extensive data
available on comorbidities, the ability to
identify racial/ethnic group in .90% of
the cohort, the longitudinal information
on the type of medication used to treat
diabetes, and the information on medica-
tion nonadherence as measured by an
MPR ,80%. There are also limitations
of our study. First, we do not have infor-
mation on plasma glucose levels and are
therefore unable to examine glucose-
independent variability in HbA1c levels.
Second, MPR is really only a proxy for
medication adherence, and because of
wastage the reliability of MPR for insulin
needs further validation; however, prior
studies of insulin MPR have been con-
ducted using VA data (25). Third, the
VAmedicalrecorddoesnotincludeinfor-
mationonsocioeconomicstatus, whichis
likely to be an important factor. Fourth,
women make up a small proportion, and
women veterans may not be representa-
tive of women in the general population.
In summary, in a national longitudi-
nal cohort of veterans with diabetes, we
found racial/ethnic disparities in HbA1c
levels and HbA1ccontrol after adjustment
for demographic characteristics, medica-
tion adherence, type of medication used
to treat diabetes, and comorbidities. As
efforts are made to better elucidate the
mechanisms of racial/ethnic disparities
in HbA1c levels, it will be important to
determine whether similar HbA1c levels
across racial/ethnic groups have the
same impact on macrovascular outcomes
andmortalityrisk.Moreover,understand-
ing geographic differences in HbA1c levels
andcontrolmayhaveimportantpolicyim-
plications if the ﬁndings are replicated in
non-VAsamplesandweareabletoidentify
factors within each setting that contribute
to differences.
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Table 3—Odds ratios and 95% CIs for poor control (HbA1c ‡8) in veterans with type 2 diabetes
Model 1* Model 2* Final model*
Racial/ethnic group (reference: NHW)
NHB 1.707 (1.683–1.732) 1.353 (1.333–1.374) 1.333 (1.311–1.354)
Hispanic 1.629 (1.595–1.664) 1.534 (1.499–1.569) 1.572 (1.536–1.608)
Other 1.905 (1.874–1.937) 1.135 (1.114–1.155) 1.245 (1.222–1.268)
Residence (rural vs. urban) 1.026 (1.014–1.037) 1.020 (1.009–1.032)
Geographic region (reference: Northeast)
South 0.952 (0.934–0.969) 0.907 (0.890–0.924)
Mid-Atlantic 1.053 (1.033–1.074) 1.007 (0.987–1.027)
Midwest 0.941 (0.922–0.959) 0.870 (0.852–0.888)
West 0.951 (0.931–0.971) 0.894 (0.875–0.913)
Age (1-year increase)† 0.959 (0.959–0.960) 0.965 (0.965–0.966)
Sex (female vs. male) 0.920 (0.888–0.953) 0.943 (0.910–0.977)
SCD (1% increase) 0.999 (0.999–1.000) 0.998 (0.998–0.999)
Marital status (single vs. married) 1.149 (1.136–1.161) 1.162 (1.149–1.175)
Medication type used to control diabetes (reference: oral hypoglycemics)
Insulin 2.349 (2.316–2.383)
Insulin and oral hypoglycemics 3.530 (3.487–3.573)
Nonadherence (MPR #80% vs. .80%) 1.048 (1.038–1.058)
Comorbidities (disease vs. no disease)
Substance abuse 1.002 (0.975–1.029)
Anemia 0.837 (0.819–0.856)
Cancer 0.924 (0.903–0.944)
Cerebrovascular disease 0.932 (0.915–0.948)
Congestive heart failure 1.136 (1.116–1.156)
Cardiovascular disease 1.065 (1.034–1.096)
Depression 1.071 (1.054–1.088)
Hypertension 0.907 (0.896–0.919)
Liver disease 0.766 (0.742–0.790)
Lung conditions 0.998 (0.973–1.004)
Electrolyte disorders 1.022 (0.997–1.048)
Obesity 0.964 (0.949–0.979)
Psychoses 0.929 (0.905–0.954)
Peripheral vascular disease 1.033 (1.016–1.051)
Other disease 0.847 (0.822–0.872)
SCD, service-connected disability. *Sequentially built models that each include time and time squared. †Age centered.
942 DIABETES CARE, VOLUME 34, APRIL 2011 care.diabetesjournals.org
Regional, geographic, and ethnic variationapprovalofthemanuscript.Thearticlerepresents
the views of the authors and not those of the VA
or Health Services Research and Development.
No potential conﬂicts of interest relevant to
this article were reported.
L.E.E. conceived and designed the study,
researched data, analyzed and interpreted
data, reviewed and edited the manuscript, and
supervised the study. M.G. and K.J.H. analyzed
andinterpreteddata,wrotethemanuscript,and
reviewed and edited the manuscript. R.N.A.,
C.E., and G.E.G. analyzed and interpreted data
and wrote the manuscript. P.D.M. conceived
and designed the study, researched data, ana-
lyzed and interpreted data, wrote the manu-
script,reviewedand editedthe manuscript, and
supervised the study.
References
1. Centers for Disease Control and Pre-
vention. National Diabetes Fact Sheet:
General Information and Estimates on Di-
abetes in the United States, 2007.A t l a n t a ,
GA, U.S. Department of Health and Hu-
man Services, 2007
2. WildS,RoglicG,GreenA,SicreeR,KingH.
Global prevalence of diabetes: estimates for
the year 2000 and projections for 2030.
Diabetes Care 2004;27:1047–1053
3. Saaddine JB, Cadwell B, Gregg EW, et al.
Improvements in diabetes processes of
care and intermediate outcomes: United
States, 1988-2002. Ann Intern Med 2006;
144:465–474
4. Healthy People 2010 [Internet]. Available
from http://www.healthypeople.gov/.
Accessed 26 May 2010
5. Herman WH, Dungan KM, Wolffenbuttel
BH, et al. Racial and ethnic differences in
mean plasma glucose, hemoglobin A1c,
and 1,5-anhydroglucitol in over 2000
patients with type 2 diabetes. J Clin En-
docrinol Metab 2009;94:1689–1694
6. Herman WH, Ma Y, Uwaifo G, et al.; Di-
abetes Prevention Program Research
Group. Differences in A1C by race and
ethnicity among patients with impaired
glucose tolerance in the Diabetes Pre-
vention Program. Diabetes Care 2007;30:
2453–2457
7. Kirk JK, D’Agostino RB Jr, Bell RA, et al.
DisparitiesinHbA1clevelsbetweenAfrican-
American and non-Hispanic white adults
with diabetes: a meta-analysis. Diabetes
Care 2006;29:2130–2136
8. Weatherspoon LJ, Kumanyika SK,
LudlowR,SchatzD.Glycemiccontrolina
sample of black and white clinic patients
with NIDDM. Diabetes Care 1994;17:
1148–1153
9. Ziemer DC, Kolm P, Weintraub WS,
et al. Glucose-independent, black-white
differences in hemoglobin A1c levels:
across-sectionalanalysisof 2studies.Ann
Intern Med 2010;152:770–777
10. Heisler M, Smith DM, Hayward RA, Krein
SL, Kerr EA. Racial disparities in di-
abetes care processes, outcomes, and
treatment intensity. Med Care 2003;41:
1221–1232
11. Kerr EA, Gerzoff RB, Krein SL, et al. Di-
abetes care quality in the Veterans Affairs
Health Care System and commercial
managed care: the TRIAD study. Ann In-
tern Med 2004;141:272–281
12. Egede LE, Mueller M, Echols CL,
Gebregziabher M. Longitudinal differences
inglycemiccontrolbyrace/ethnicityamong
veterans with type 2 diabetes. Med Care
2010;48:527–533
13. Andrus MR, Kelley KW, Murphey LM,
Herndon KC. A comparison of diabetes
care in rural and urban medical clinics in
Alabama. J Community Health 2004;29:
29–44
14. Weingarten JP Jr, Brittman S, Hu W,
PrzybyszewskiC,HammondJM,FitzGerald
D. The state of diabetes care provided
to Medicare beneﬁciaries living in rural
America. J Rural Health 2006;22:351–358
15. Kirkbride K, Wallace N. Rural health
clinics and diabetes-related primary care
for Medicaid beneﬁciaries in Oregon. J
Rural Health 2009;25:247–252
16. Weeks WB, Bott DM, Lamkin RP, Wright
SM. Veterans Health Administration and
Medicare outpatient health care utiliza-
tion by older rural and urban New Eng-
land veterans. J Rural Health 2005;21:
167–171
17. Voeks JH, McClure LA, Go RC, et al. Re-
gional differences in diabetes as a possible
contributor to the geographic disparity in
stroke mortality: the REasons for Geo-
graphic And Racial Differences in Stroke
Study. Stroke 2008;39:1675–1680
18. Miller DR, Safford MM, Pogach LM. Who
has diabetes? Best estimates of diabetes
prevalenceintheDepartmentofVeterans
Affairs based on computerized patient
data. Diabetes Care 2004;27(Suppl. 2):
B10–B21
19. West AN,LeeRE,Shambaugh-Miller MD,
et al. Deﬁning “rural” for veterans’ health
care planning. J Rural Health 2010;26:
301–309
20. Department of Veterans Affairs Field Re-
search Advisory Committee. Department
of Veterans Affairs, Veterans Health
Administration, Ofﬁce of Research and
Development, Field Research Advisory
Committee Operating Procedures [Inter-
net], 2004. Available from http://www.
research.va.gov/about/frac/FRAC-ops.pdf.
Accessed 19 February 2011
21. Diggle PJ, Heagerty P, Liang K-Y, Zeger
SL. Analysis of Longitudinal Data. 2nd ed.
Oxford, England, Oxford University
Press, 2002
22. Twombly JG, Long Q, Zhu M, et al. Di-
abetes care in black and white veterans in
thesoutheasternU.S.DiabetesCare2010;
33:958–963
23. Heisler M, Faul JD, Hayward RA, Langa
KM, Blaum C, Weir D. Mechanisms for
racial and ethnic disparities in glycemic
controlinmiddle-agedandolderAmericans
in the health and retirement study. Arch
Intern Med 2007;167:1853–1860
24. Nathan DM, Kuenen J, Borg R, Zheng H,
Schoenfeld D, Heine RJ; A1c-Derived
AverageGlucoseStudyGroup.Translating
the A1C assay into estimated average glu-
cose values. Diabetes Care 2008;31:1473–
1478
25. Cramer JA, Pugh MJ. The inﬂuence of
insulin use on glycemic control: how well
do adults follow prescriptions for insulin?
Diabetes Care 2005;28:78–83
Figure1—Oddsratiosand95%CIsforpoorcontrol(HbA1c$8)inveteranswithtype2diabetes,
ﬁnal model.
care.diabetesjournals.org DIABETES CARE, VOLUME 34, APRIL 2011 943
Egede and Associates